他汀类药物的临床应用及不良反应研究进展

被引:47
作者
张冰
王莉莉
机构
[1] 军事医学科学院毒物药物研究所
关键词
他汀类; 临床应用; 不良反应; 肝毒性; 肌毒性;
D O I
10.13220/j.cnki.jipr.2013.05.016
中图分类号
R972.6 [];
学科分类号
摘要
他汀类药物是一线降脂药物,也是心血管疾病的预防药物,临床应用和研究范围正不断扩大。他汀类药物临床应用研究主要关注心血管疾病一级预防、充血性心力衰竭的治疗、对糖尿病发病的影响等。近年来,他汀类药物的不良反应,特别是肝毒性和肌毒性也愈发引起人们的关注。肝毒性主要表现为转氨酶升高,严重者引起肝功能衰竭;肌毒性主要表现为肌痛、抽搐等,严重者会引起横纹肌溶解症。临床上主要采用监测血清丙氨酸转氨酶或磷酸肌酸激酶,结合临床表现并及时减量或停药的方法来防止严重不良反应的发生,一些新的治疗方案还在研究中。深入研究他汀类药物不良反应的发生机制,开发有效的辅助治疗方法或复方药物有助于该类药物的安全应用。
引用
收藏
页码:560 / 564+572 +572
页数:6
相关论文
共 41 条
  • [1] Liver toxicity of rosuvastatin therapy[J]. Giuseppe Famularo,Luca Miele,Giovanni Minisola,Antonio Grieco.World Journal of Gastroenterology. 2007(08)
  • [2] Statins for primary prevention of cardiovascular disease: the benefits outweigh the risks[J] . C. Michael Minder,Roger S. Blumenthal,Michael J. Blaha.Current Opinion in Cardiology . 2013 (5)
  • [3] Long-term Clinical Outcomes of Statin Use for Chronic Heart Failure: A Meta-analysis of 15 Prospective Studies[J] . Jian-Qiang Wang,Guo-Rong Wu,Zheng Wang,Xiao-Ping Dai,Xiang-Rong Li.Heart, Lung and Circulation . 2013
  • [4] Protective effects of l -carnitine and piracetam against mitochondrial permeability transition and PC3 cell necrosis induced by simvastatin[J] . Rute A.P. Costa,Mariana P. Fernandes,Nadja C. de Souza-Pinto,Aníbal E. Vercesi.European Journal of Pharmacology . 2013 (1-3)
  • [5] Pharmacological activation of the pyruvate dehydrogenase complex reduces statin-mediated upregulation of FOXO gene targets and protects against statin myopathy in rodents
    Mallinson, Joanne E.
    Constantin-Teodosiu, Dumitru
    Glaves, Philip D.
    Martin, Elizabeth A.
    Davies, Wendy J.
    Westwood, F. Russell
    Sidaway, James E.
    Greenhaff, Paul L.
    [J]. JOURNAL OF PHYSIOLOGY-LONDON, 2012, 590 (24): : 6389 - 6402
  • [6] Nitric oxide prevents atorvastatin‐induced skeletal muscle dysfunction and alterations in mice[J] . Giuseppe D’Antona,Anna Mascaro,Angela Monopoli,Daniela Miglietta,Ennio Ongini,Roberto Bottinelli.Muscle Nerve . 2012 (1)
  • [7] Statins are diabetogenic – Myth or reality?[J] . Naveed Sattar,Marja-Riitta Taskinen.Atherosclerosis (Supplements) (Component) . 2012 (1)
  • [8] Statin induced myotoxicity
    Sathasivam, Sivakumar
    [J]. EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2012, 23 (04) : 317 - 324
  • [9] Muscle mitochondrial metabolism and calcium signaling impairment in patients treated with statins
    Sirvent, P.
    Fabre, O.
    Bordenave, S.
    Hillaire-Buys, D.
    De Mauverger, E. Raynaud
    Lacampagne, A.
    Mercier, J.
    [J]. TOXICOLOGY AND APPLIED PHARMACOLOGY, 2012, 259 (02) : 263 - 268
  • [10] Statins in Heart Failure: The Paradox Between Large Randomized Clinical Trials and Real Life[J] . Paloma Gastelurrutia,Josep Lupón,Marta de Antonio,Agustin Urrutia,Crisanto Díez,Ramón Coll,Salvador Altimir,Antoni Bayes-Genis.Mayo Clinic Proceedings . 2012 (6)